The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease
Open accessAbstract
The complement system constitutes a series of enzymatic steps involved in the inflammatory response and is activated in Alzheimer's disease (AD). Using Down's syndrome (DS) brains as a temporal model for the progression of AD, we examined components of the complement cascade and their relationship to other principal events in AD pathology: Abeta42 deposition, neuritic changes, neurofibrillary tangles (NFTs), and gliosis (reactive astrocytes, activated microglia). Adjacent sections of frontal cortex from 24 DS subjects ranging in age from 12 to 73 years were immunohistochemically examined for immunoreactivity (IR) of classical complement proteins (Clq and C3), markers indicating activation of complement (C4d and C5b-9), the complement inhibitor apolipoprotein J (apo J), and markers of AD neuropathology. Abeta42-labeled diffuse plaques were first detected in a 12-year-old DS subject and were not labeled by any of the complement antibodies. Colocalization of Abeta42 with Clq, C3, C4d, and/or apo J was first detected in compacted plaques in the brain of a 15-year-old DS patient with features of mature AD pathology, such as reactive astrocytes, activated microglia, dystrophic neurites, and a few NFTs. IR for C4d and C5b-9 (membrane attack complex, MAC) was observed in small numbers of plaque-associated dystrophic neurites and in focal regions of pyramidal neurons in this 15-year-old. The only other young (</=30 years) DS brain to show extensive complement IR was that of a 29-year-old DS subject who also displayed the full range of AD neuropathological features. All middle-aged and old DS brains showed IR for Clq and C3, primarily in compacted plaques. In these cases, C4d IR was found in a subset of Abeta42 plaques and, along with C5b-9 IR, was localized to dystrophic neurites in a subset of neuritic plaques, neurons, and some NFTs. Our data suggest that in AD and DS, the classical complement cascade is activated after compaction of Abeta42 deposits and, in some instances, can progress to the local neuronal expression of the MAC as a response to Abeta plaque maturation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Complement activation is elevated in human AD brain, especially in the presence of fibrillar amyloid plaques containing clusters of reactive microglia (8, 9, 11, 12)”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In humans, early, non-fibrillar diffuse plaques are associated with little or no microglial clustering (53) and accumulate little or no complement proteins (8, 9).”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, at later stages of AD pathogenesis in humans, various complement proteins and clusters of activated microglia have been found to colocalize with fibrillar amyloid plaques, often containing dystrophic neurites (8, 9).”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Strong evidence has implicated the complement system in the pathogenesis of Alzheimer’s disease [72–76]”
In the citing paper
“Complement cascade components, including C3 are significantly upregulated and associated with amyloid plaques, typically containing dystrophic neurites, in human AD (8, 9)”
From Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice (2017) · cites this paper as [8]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,778
Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.4044 · Cited by 1,459
Self-citationMCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Translating cell biology into therapeutic advances in Alzheimer's disease
Selkoe, D. J. (1999) · Nature · doi:10.1038/399a023 · Cited by 1,166
Self-citationOccurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159 · cited 1×
“The development of amyloid deposits was described in teenage DS subjects by silver staining techniques.(7) Subsequently, sensitive antibodies to Ab42 were used to detect abundant diffuse Ab42 plaques (thioflavin S negative) as early as 12 years in DS.”
MethodSelf-citationComplement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease
Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., Martins, R., Hockey, A., Montgomery, P., Beyreuther, K., & Masters, C. L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906013202203 · Cited by 653
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 5×
“Moreover, the large number of activated microglia, reactive astrocytes, and dystrophic neurites, as markers of inflammation and potential sources of complement proteins, suggests that the cascade is active in the AD-type lesions that occur in DS. Apo J, a known inhibitor of C5b-9, showed much more IR than either C4d o…”
BackgroundInfluentialSelf-citationA Prospective Study of Alzheimer Disease in Down Syndrome
Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561
(1997) · doi:10.1073/pnas.94.4.1550 · Cited by 535
Research works printed but not linked: 2
- Mann, 1992, The time course of pathological events in Down's syndrome with particular reference to the involvement of microglial cells and deposits of β/A4, Neurodegeneration, 1, 201
- Kolb, 1988, Development of a highly sensitive capture EIA for the quantitation of the SC5b-9 complex in human plasma using a monoclonal antibody reactive with a poly-C9 neoantigenic determinant, Complement, 5, 213
Cited by
Inflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6295 · Cited by 593
“This possibility would be consistent with our previous findings that genetic deletion or antibody blocking of C1qa protected hippocampal synapses from Ab oligomer–induced damage (8).”
BackgroundResultInfluentialSelf-citationAstrocyte apoptosis: implications for neuroprotection
Takuma, K., Baba, A., & Matsuda, T. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.02.001 · Cited by 435
Microglia and Inflammation in Alzheimers Disease
Mandrekar-Colucci, S., & Landreth, G. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012071 · Cited by 421
Metadata
- Authors
- Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Lemere, Cynthia A.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2000-02
- Volume
- 156
- Issue
- 2
- Pages
- 489-499
- ISSN
- 0002-9440 (ISSN-L)
- PMC
- PMC1850044
- OpenAlex
- W2011141622
- Cited by
- 187
- References
- 41
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 21 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 5 · 2018: 8 · 2017: 5 · 2016: 2 · 2015: 8 · 2014: 4 · 2013: 6 · 2012: 7
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- American Journal Of Pathology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-06173, AG15408, R01AG015408, R37AG006173, RF1AG006173, R01AG006173)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- complement system, Down syndrome, Alzheimer's disease, amyloid plaques, amyloid-beta 42, classical complement pathway, C4d, membrane attack complex, clusterin, neuritic plaques, neurofibrillary tangles, gliosis, dystrophic neurites, frontal cortex, temporal development
- MeSH terms
- Adolescent, Adult, Aged, Alzheimer Disease, Brain, Child, Complement System Proteins, Complement C4, Down Syndrome, Glycoproteins, Humans, Middle Aged, Peptide Fragments, Time Factors, Complement C4b, Complement Membrane Attack Complex, Disease Progression, Molecular Chaperones, Clusterin, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease. https://app.cochat.ai/papers/10.1016/s0002-9440(10)64753-0
- The paper
- Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000). Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease. The American Journal of Pathology. https://doi.org/10.1016/s0002-9440(10)64753-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.